Research programme: bleeding therapeutics (Ebola virus) - Fibreu Limited
Latest Information Update: 10 Aug 2016
At a glance
- Originator Fibreu
- Class Acute-phase proteins
- Mechanism of Action Fibrinogen replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haemorrhage
Most Recent Events
- 10 Aug 2016 Preclinical trials in Haemorrhage in United Kingdom (unspecified route)
- 12 Feb 2015 Research programme: bleeding therapeutics (Ebola virus) - Fibreu Limited receives Orphan Drug status for Haemorrhage in European Union